{"denoms":[{"counts":[{"groupId":"BG000","value":"252"},{"groupId":"BG001","value":"248"},{"groupId":"BG002","value":"500"}],"units":"Participants"}],"groups":[{"description":"Participants received 8 cycles of investigator's choice of neoadjuvant chemotherapy. This included either: 1) 4 cycles of dose-dense doxorubicin plus cyclophosphamide (ddAC) once every 2 weeks (Q2W) (given with granulocyte colony-stimulating factor \\[G-CSF\\] support as needed according to local guidelines) followed by paclitaxel QW for 12 weeks; or 2) 4 cycles of doxorubicin plus cyclophosphamide (AC) once every 3 weeks (Q3W) followed by docetaxel Q3W for 4 cycles. Pertuzumab and trastuzumab were given intravenously (IV) for 4 cycles Q3W concurrently with the taxane component of chemotherapy. After completing their neoadjuvant therapy, participants underwent surgery. Thereafter, participants received an additional 14 cycles of pertuzumab IV and trastuzumab IV for a total of 18 cycles.","id":"BG000","title":"Arm A: Pertuzumab IV + Trastuzumab IV + Chemotherapy"},{"description":"Participants received 8 cycles of investigator's choice of neoadjuvant chemotherapy. This included either: 1) 4 cycles of ddAC Q2W (given with G-CSF support as needed according to local guidelines) followed by paclitaxel once every week (QW) for 12 weeks; or 2) 4 cycles of AC Q3W followed by docetaxel Q3W for 4 cycles. The fixed-dose combination (FDC) of pertuzumab and trastuzumab was given subcutaneously (SC) for 4 cycles (Q3W) concurrently with the taxane component of chemotherapy. After completing their neoadjuvant therapy, participants underwent surgery. Thereafter, participants received an additional 14 cycles of the FDC of pertuzumab and trastuzumab SC for a total of 18 cycles.","id":"BG001","title":"Arm B: Pertuzumab and Trastuzumab FDC SC + Chemotherapy"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"10.8","value":"50.3"},{"groupId":"BG001","spread":"10.7","value":"51.7"},{"groupId":"BG002","spread":"10.8","value":"51.0"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"250"},{"groupId":"BG001","value":"248"},{"groupId":"BG002","value":"498"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"32"},{"groupId":"BG001","value":"42"},{"groupId":"BG002","value":"74"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"200"},{"groupId":"BG001","value":"189"},{"groupId":"BG002","value":"389"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"20"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"37"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"20"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"54"},{"groupId":"BG001","value":"51"},{"groupId":"BG002","value":"105"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"6"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"164"},{"groupId":"BG001","value":"165"},{"groupId":"BG002","value":"329"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"5"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"19"},{"groupId":"BG001","value":"16"},{"groupId":"BG002","value":"35"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"97"},{"groupId":"BG001","value":"96"},{"groupId":"BG002","value":"193"}],"title":"ER Negative and PgR Negative"},{"measurements":[{"groupId":"BG000","value":"155"},{"groupId":"BG001","value":"151"},{"groupId":"BG002","value":"306"}],"title":"ER Positive and PgR Positive"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"}],"title":"Unknown"}]}],"description":"Hormone receptor status was based on central assessment of participant samples for estrogen receptor (ER) and progesterone receptor (PgR) negativity or positivity.","paramType":"COUNT_OF_PARTICIPANTS","title":"Randomization Stratification Factors: Hormone Receptor Status","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"201"},{"groupId":"BG001","value":"198"},{"groupId":"BG002","value":"399"}],"title":"Stage II-IIIA"},{"measurements":[{"groupId":"BG000","value":"51"},{"groupId":"BG001","value":"50"},{"groupId":"BG002","value":"101"}],"title":"Stage IIIB-IIIC"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Randomization Stratification Factors: Clinical Stage at Presentation","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"120"},{"groupId":"BG001","value":"120"},{"groupId":"BG002","value":"240"}],"title":"ddAC Followed by Paclitaxel"},{"measurements":[{"groupId":"BG000","value":"132"},{"groupId":"BG001","value":"128"},{"groupId":"BG002","value":"260"}],"title":"AC Followed by Docetaxel"}]}],"description":"AC = doxorubicin plus cyclophosphamide; ddAC = dose-dense doxorubicin plus cyclophosphamide","paramType":"COUNT_OF_PARTICIPANTS","title":"Randomization Stratification Factors: Neoadjuvant Chemotherapy Regimen","unitOfMeasure":"Participants"}]}